Charles Schwab Investment Management Inc. Purchases New Position in TuHURA Biosciences (NASDAQ:HURA)

Charles Schwab Investment Management Inc. purchased a new position in TuHURA Biosciences (NASDAQ:HURA) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 15,000 shares of the company’s stock, valued at approximately $61,000.

Separately, Apollon Wealth Management LLC bought a new position in shares of TuHURA Biosciences in the 4th quarter worth approximately $253,000. Hedge funds and other institutional investors own 0.62% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on HURA. HC Wainwright began coverage on TuHURA Biosciences in a research note on Monday, March 3rd. They issued a “buy” rating and a $13.00 price target on the stock. RODMAN&RENSHAW upgraded shares of TuHURA Biosciences to a “strong-buy” rating in a research note on Thursday, December 19th. Finally, Rodman & Renshaw initiated coverage on shares of TuHURA Biosciences in a research note on Thursday, December 19th. They set a “buy” rating and a $11.00 price objective on the stock.

TuHURA Biosciences Stock Performance

NASDAQ HURA opened at $2.91 on Wednesday. TuHURA Biosciences has a 12 month low of $1.80 and a 12 month high of $7.93. The business has a fifty day moving average of $3.49.

TuHURA Biosciences Company Profile

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.